CU22584A1 - Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis - Google Patents

Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis

Info

Publication number
CU22584A1
CU22584A1 CU1995120A CU1995120A CU22584A1 CU 22584 A1 CU22584 A1 CU 22584A1 CU 1995120 A CU1995120 A CU 1995120A CU 1995120 A CU1995120 A CU 1995120A CU 22584 A1 CU22584 A1 CU 22584A1
Authority
CU
Cuba
Prior art keywords
pharmaceutical compositions
monoclonal antibody
recognizes
psoriasis
compositions containing
Prior art date
Application number
CU1995120A
Other languages
English (en)
Inventor
Blazquez Patricia Sierra
Valladares Josefa Lombardero
Casimiro Jose Enrique Montero
Bravo Blanca Rosa Tormo
Rodriguez Rolando Perez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Priority to CU1995120A priority Critical patent/CU22584A1/es
Priority to AT96939805T priority patent/ATE280783T1/de
Priority to DE69633717T priority patent/DE69633717T2/de
Priority to US08/875,674 priority patent/US6572857B1/en
Priority to DK96939805T priority patent/DK0807125T3/da
Priority to CA002210751A priority patent/CA2210751C/en
Priority to CNB96192098XA priority patent/CN1222540C/zh
Priority to JP51926797A priority patent/JP4113929B2/ja
Priority to PT96939805T priority patent/PT807125E/pt
Priority to KR1019970704893A priority patent/KR100533854B1/ko
Priority to PCT/CU1996/000004 priority patent/WO1997019111A2/es
Priority to BRPI9607171A priority patent/BRPI9607171B1/pt
Priority to AU76905/96A priority patent/AU722882B2/en
Priority to ES96939805T priority patent/ES2231826T3/es
Priority to EP96939805A priority patent/EP0807125B1/en
Priority to MXPA/A/1997/005445A priority patent/MXPA97005445A/es
Publication of CU22584A1 publication Critical patent/CU22584A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con la rama de la Inmunología y en particular con la obtención de composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario CD6. De acuerdo con lo expuesto, el objeto de esta invención es proporcionar composiciones farmacéuticas que contengan un anticuerpo monoclonal anti CD6 para el diagnóstico y tratamiento de lesiones cutáneas de la Psoriasis Vulgar. La esencia de la invención consiste en aplicar un anticuerpo monoclonal que reconoce el antígeno CD&, obtener composiciones farmacéuticas que contengan este anticuerpo y sean capaces de lograr una efectividad clínica e histológica en pacientes con las diferentes formas clínicas de la Psoriasis. El campo de aplicación de la presente invención se extiende a la Dermatología.
CU1995120A 1995-11-17 1995-11-17 Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis CU22584A1 (es)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CU1995120A CU22584A1 (es) 1995-11-17 1995-11-17 Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
AT96939805T ATE280783T1 (de) 1995-11-17 1996-11-18 Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
DE69633717T DE69633717T2 (de) 1995-11-17 1996-11-18 Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
US08/875,674 US6572857B1 (en) 1995-11-17 1996-11-18 Anti-CD6 monoclonal antibodies and their uses
DK96939805T DK0807125T3 (da) 1995-11-17 1996-11-18 Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis
CA002210751A CA2210751C (en) 1995-11-17 1996-11-18 Anti-cd6 monoclonal antibodies and their uses
CNB96192098XA CN1222540C (zh) 1995-11-17 1996-11-18 抗cd6的单克隆抗体和它们的用途
JP51926797A JP4113929B2 (ja) 1995-11-17 1996-11-18 アンチｃｄ６モノクロナール抗体とその利用
PT96939805T PT807125E (pt) 1995-11-17 1996-11-18 Anticorpos monoclonais anti-cd6 para o tratamento e diagnose da psoriase
KR1019970704893A KR100533854B1 (ko) 1995-11-17 1996-11-18 항-cd6 단일클론항체 및 이를 포함하는 건선치료용 약제조성물
PCT/CU1996/000004 WO1997019111A2 (es) 1995-11-17 1996-11-18 Anticuerpos monoclonales anti-cd6 y sus utilizaciones
BRPI9607171A BRPI9607171B1 (pt) 1995-11-17 1996-11-18 anticorpo monoclonal anti-cd6 humano, usos dos mesmos para o diagnóstico in vitro de psoríase, composição farmacêutica e reagente contendo o dito anticorpo
AU76905/96A AU722882B2 (en) 1995-11-17 1996-11-18 Anti-CD6 monoclonal antibodies and their uses
ES96939805T ES2231826T3 (es) 1995-11-17 1996-11-18 Anticuerpos monoclonales anti-cd6 para el tratamiento y el diagnostico de la psoriasis.
EP96939805A EP0807125B1 (en) 1995-11-17 1996-11-18 Monoclonal antibodies anti-cd6 for the treatment and diagnosis of psoriasis
MXPA/A/1997/005445A MXPA97005445A (es) 1995-11-17 1997-07-17 Anticuerpos monoclonales anti-cd6 y sus usos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1995120A CU22584A1 (es) 1995-11-17 1995-11-17 Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis

Publications (1)

Publication Number Publication Date
CU22584A1 true CU22584A1 (es) 1999-11-03

Family

ID=5459401

Family Applications (1)

Application Number Title Priority Date Filing Date
CU1995120A CU22584A1 (es) 1995-11-17 1995-11-17 Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis

Country Status (15)

Country Link
US (1) US6572857B1 (es)
EP (1) EP0807125B1 (es)
JP (1) JP4113929B2 (es)
KR (1) KR100533854B1 (es)
CN (1) CN1222540C (es)
AT (1) ATE280783T1 (es)
AU (1) AU722882B2 (es)
BR (1) BRPI9607171B1 (es)
CA (1) CA2210751C (es)
CU (1) CU22584A1 (es)
DE (1) DE69633717T2 (es)
DK (1) DK0807125T3 (es)
ES (1) ES2231826T3 (es)
PT (1) PT807125E (es)
WO (1) WO1997019111A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215450A1 (en) * 2000-05-26 2003-11-20 Blake Simon M Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
CU23097A1 (es) 2002-10-23 2005-11-18 Centro Inmunologia Molecular Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
CA2516971A1 (en) 2003-02-24 2004-09-02 Institut Pasteur Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof
CA2676185C (en) * 2006-12-26 2013-03-12 Centro De Inmunologia Molecular Pharmaceutical composition, comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
CN101678101B (zh) 2006-12-26 2012-11-07 分子免疫中心 可用于诊断和治疗b细胞慢性淋巴细胞白血病的能够在肿瘤细胞中诱导凋亡的药物组合物
MX2010007551A (es) 2008-01-11 2010-11-30 Synovex Corp Antagonistas de la cadherina-11 y metodos para el tratamiento de trastornos inflamatorios de las articulacion.
EP2993186B1 (en) * 2008-03-14 2019-09-04 Biocon Limited A monoclonal antibody and a method thereof
BR112013001062A2 (pt) * 2010-07-15 2016-05-24 Synovex Corp anticorpos humanizados que visam o domínio ec1 de caderina-11 e composições e métodos relacionados
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
BR112013033988B1 (pt) 2011-07-01 2021-10-19 Beckman Coulter, Inc. Métodos de identificação e isolamento de uma ou mais populações de células t regulatórias imunossupressoras
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HRP20220250T1 (hr) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
SI2791160T1 (sl) 2011-12-16 2022-07-29 Modernatx, Inc. Sestave modificirane MRNA
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
FR3000216B1 (fr) * 2012-12-21 2015-02-06 Galderma Res & Dev Utilisation de proteases particulieres pour la detection de trichophytons et de pathologies associees
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3936148A1 (en) 2013-07-23 2022-01-12 Biocon Limited Use of a cd6 binding partner and method based thereon
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
CN105504062B (zh) * 2015-12-25 2019-06-04 百泰生物药业有限公司 一种抗CD6单抗T1h的检测性抗体及应用
EP3529274B1 (en) 2016-10-21 2024-04-17 Biocon Limited A monoclonal antibody and a method of use for the treatment of lupus
AU2019228508A1 (en) * 2018-02-27 2020-09-17 Equillium, Inc. Anti CD6 antibodies for treating severe asthma
WO2020006568A1 (en) 2018-06-29 2020-01-02 City Of Hope Cd6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders
EP3930751A1 (en) 2019-02-26 2022-01-05 Equillium, Inc. Anti-cd6 antibody compositions and methods for treating lupus
EP4084808A1 (en) 2019-12-30 2022-11-09 City of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
CA3231281A1 (en) 2021-09-08 2023-03-16 Yanelda De Los Angeles Garcia Vega Use of anti-cd6 monoclonal antibodies in the prevention of cellular and organ damage resulting from hyper-inflammatory response
WO2025096685A1 (en) 2023-10-30 2025-05-08 City Of Hope Methods of making and using regulatory t cells for treatment of autoimmune disorders and cancers
CN120005027B (zh) * 2025-04-10 2025-09-23 中国水产科学研究院长江水产研究所 大口黑鲈cd6抗原结合肽、及其单克隆抗体和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012614A1 (en) * 1993-11-02 1995-05-11 Duke University Cd6 ligand
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos

Also Published As

Publication number Publication date
WO1997019111A2 (es) 1997-05-29
JPH11506017A (ja) 1999-06-02
DK0807125T3 (da) 2005-03-14
JP4113929B2 (ja) 2008-07-09
CA2210751C (en) 2007-01-30
BRPI9607171B1 (pt) 2016-07-19
US6572857B1 (en) 2003-06-03
DE69633717T2 (de) 2006-02-02
KR100533854B1 (ko) 2006-09-20
MX9705445A (es) 1998-06-30
PT807125E (pt) 2005-03-31
WO1997019111A3 (es) 1998-02-12
CN1222540C (zh) 2005-10-12
CN1175957A (zh) 1998-03-11
BR9607171A (pt) 1997-11-11
ATE280783T1 (de) 2004-11-15
KR19980701502A (ko) 1998-05-15
ES2231826T3 (es) 2005-05-16
EP0807125B1 (en) 2004-10-27
AU722882B2 (en) 2000-08-10
DE69633717D1 (de) 2004-12-02
EP0807125A2 (en) 1997-11-19
CA2210751A1 (en) 1997-05-29
AU7690596A (en) 1997-06-11

Similar Documents

Publication Publication Date Title
CU22584A1 (es) Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
CU23251A3 (es) Formulaciones liquidas estables de toxina botulinica
FR2810539B1 (fr) Procede et dispositif de traitement,notamment de maquillage, de coloration ou de soin cosmetique,de parties ou de la totalite du corps humain ou animal
Van Praag et al. Determination of the photoprotective efficacy of a topical sunscreen against UVB-induced DNA damage in human epidermis
ES2060310T3 (es) Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion.
MX9801596A (es) Composiciones aliviadoras del prurito, cosmeticas y farmaceuticas o ambas.
Murphy et al. Sunbed‐induced pseudoporphyria
Nestor et al. Efficacy and tolerability of a combined 445nm and 630nm over-the-counter light therapy mask with and without topical salicylic acid versus topical benzoyl peroxide for the treatment of mild-to-moderate acne vulgaris
Mostafa et al. Modulation of autophagy, apoptosis and oxidative stress: A clue for repurposing metformin in photoaging
Lehmann Photodermatoses
Rongioletti et al. Erosive pustular dermatosis of the scalp induced by ingenol mebutate.
DK0709097T3 (da) Anti-Fas antistof mod reumatiske sygdomme
Giovinazzo et al. Photoallergic contact dermatitis to musk ambrette: histopathologic features of photobiologic reactions observed in a persistent light reactor
Lamberg Symptomatic pitted keratolysis
AR004355A1 (es) Anticuerpos monoclonales anti-cd6 y sus usos.
ES2161987T3 (es) Parche/pelicula radioactiva y procedimiento para la preparacion de la misma.
Jiyad et al. Handbook of Skin Disease Management
BR9504089A (pt) Agente para o tratamento ou cuidado de pele irritada ou inflamada e aplicação
Goette Basal cell carcinomas arising in seborrheic keratoses
Young et al. Functional and morphological changes in pig skin after single or fractionated doses of X rays
Eber et al. Photodynamic therapy
Willis Photosensitivity.
Poh-Fitzpatrick The biologic actions of solar radiation on skin with a note on sunscreens
Basdew et al. Adjunctive treatment of keloids: comparison of photodynamic therapy with brachytherapy
Prohic Dermatological Therapy